RenovoRx (RNXT) to Release Quarterly Earnings on Monday

RenovoRx (NASDAQ:RNXT) is anticipated to release its earnings data before the market opens on Monday, April 7th. Analysts expect RenovoRx to post earnings of ($0.12) per share for the quarter.

RenovoRx Stock Down 2.0 %

RenovoRx stock opened at $1.00 on Monday. RenovoRx has a 12 month low of $0.77 and a 12 month high of $1.69. The stock has a market cap of $24.00 million, a P/E ratio of -1.75 and a beta of 1.15. The company’s fifty day simple moving average is $1.12 and its 200-day simple moving average is $1.15.

Analysts Set New Price Targets

RNXT has been the topic of several research reports. HC Wainwright started coverage on RenovoRx in a research report on Thursday. They issued a “buy” rating and a $3.00 target price on the stock. Ascendiant Capital Markets increased their price objective on RenovoRx from $8.25 to $9.00 and gave the stock a “buy” rating in a report on Tuesday, December 10th.

RenovoRx Company Profile

RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.